Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
AI Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
clinical manuacturing
Pharma
Boehringer Ingelheim divests biologics CDMO unit in China
Blood products developer Raas will pay up to around $3 million to secure a 100% stake in a Boehringer Ingelheim biologics CDMO unit in China.
Fraiser Kansteiner
Sep 24, 2026 11:38am
Merck KGaA charts biggest deal in 10+ years with Bio-Techne buy
Jun 25, 2026 9:56am
FDA unveils 1-day assessment pilot to complement inspections
May 6, 2026 3:08pm
Kyowa Kirin wraps up build out of $118M biologics plant
Apr 11, 2025 10:00am
Lantheus snaps up radiopharma CDMO Evergreen for $250M+
Jan 28, 2025 10:08am
GSK embarks on PA manufacturing expansion worth up to $800M
Oct 24, 2024 4:05pm